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ImmunotherapyFatal insomnia (FI) is the ﬁrst diagnosis to be considered by most neurologists when approaching a patient
presenting with total insomnia followed by personality and cognitive changes, disturbance of alertness, auto-
nomic hyperactivation and movement abnormalities.
We report the case of a 30 year-old male patient who presented with total insomnia followed by episodes of
psychomotor restlessness resembling anxiety attacks. Twenty days later, he developed refractory convulsive
status epilepticus with admission to Intensive Care Unit. He progressed to a state of reduced alertness and
responsiveness, presenting periods of agitation with abnormal dyskinetic movements, periods of autonomic
instability and central hypoventilation. Workup revealed antibodies against N-methyl-D-aspartate receptor
(NMDAR). Immunotherapy treatment led to a very signiﬁcant improvement with the patient presenting only
slight frontal lobe dysfunction after one year of recovery.
To the best of our knowledge this is the ﬁrst report of a patient with anti-NMDAR encephalitis ﬁrst presenting
with total insomnia. Our aim is to alert that anti-NMDAR encephalitis must be considered in the differential
diagnosis of FI, especially in sporadic cases. Distinguishing the two conditions is very important as, contrarily
to the fatal disclosure of FI, anti-NMDAR encephalitis is potentially reversible with adequate treatment even
after severe and prolonged disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
When approaching a patient presenting with total insomnia follow-
ed by personality and cognitive changes, disturbance of alertness, auto-
nomic hyperactivation and motor abnormalities, fatal insomnia (FI) is
the ﬁrst diagnosis to be considered. Although FI is more commonly a
hereditary disease, this diagnosis may also be considered in patients
without family history as sporadic cases have also been described [1].
In the present article we report the case of a young male patient
who presented with total insomnia followed by behavioral changes,
seizures and alertness decrease associated with abnormal movements,
autonomic hyperactivation and central hypoventilation,whichdiagnostic
workup revealed anti-N-methyl-D-aspartate receptor (NMDAR) enceph-
alitis. A signiﬁcant clinical improvement occurred after immunotherapy.
1.1. Case report
A 30 year-oldmale patientwith unremarkable personal and familial
pastmedical history presentedwith total insomnia of sudden onset. Four
days later, he developed recurrent episodes of psychomotor restlessness,
tachycardia, generalized tremors, diaphoreses and dyspneawith approx-
imately 20 minute duration and was taken to the Emergency Room.351 239 822 637.
ues).
ights reserved.Alprazolamwas prescribed for anxiety disorder, however total insomnia
persisted, the episodes of restlessness increased in frequency, occurring
8 to 10 times per day, and the patient became irritable and aggressive.
He was admitted to a Psychiatric Department two days later and medi-
cated with olanzapine, diazepam, haloperidol and valproic acid with no
clinical improvement. Twenty days later, he developed hyperthermia
(39.7 °C) and refractory generalized tonic–clonic seizures requiring
anesthesia with propofol and midazolam. He was transferred to an In-
tensive Care Unit and empirical treatment with acyclovir, ceftriaxone,
dantrolene and bromocriptine was started, considering the hypothesis
of central nervous system infection or neuroleptic malignant syndrome.
Blood workup including complete blood count, coagulation study,
biochemistry and serological testing (Herpes simplex virus type 1 and
type 2, Cytomegalovirus, Enterovirus, Echovirus, Adenovirus, Coxsackie
virus, Coxiella burnetii, Toxoplasma gondii, Measles, Mumps, Treponema
pallidum, Borrelia burgdorferi and Brucella) was unremarkable, as well
as cerebrospinal ﬂuid (CSF) cytochemical analysis, serological testing
(Herpes simplex virus type 1 and type 2, Cytomegalovirus, Measles, Ad-
enovirus, Coxsackie virus and Echovirus) and cultures. Brain computed
tomography (CT) scan and magnetic resonance imaging (MRI) did not
reveal any abnormal ﬁndings. Electroencephalogram (EEG) showed
slow activity and sparse epileptic activity in the right frontal region.
Several attempts towithdrawanesthetic treatmentwere performeddur-
ing the following fourweeks, but refractory convulsive status epilepticus
always recurred.
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to our hospital in order to perform continuous video-EEGmonitoring. At
admittance, EEG revealed diffuse slow activity andnon-continuous focal
seizures, so anesthetic discontinuationwas tried oncemore. Fluctuation
of alertness and diminished responsiveness were observed, with pe-
riods of total unresponsiveness alternating with periods of dissociative
responses to stimuli, characterized by absent response to painful or
visual stimuli but resistance to attempts of eyelid opening. Periods of
total immobility and generalized hypertonia (Video 1) alternated with
periods of agitation with abnormal movements, mainly involving the
left upper limb and oromandibular muscles, with variable dyskinetic
movements including tremor, choreoathetosis, dystonia and abnormal
postures (Videos 2–4). Dyskinetic movements involving the trunk and
the remaining limbs were also noticed although less frequently (Video
5). Periods of autonomic instability were identiﬁed consisting of tachy-
cardia, arterial hypertension, diaphoresis and hyperthermia. Central
hypoventilation was also present, with inability to suspend invasive
ventilation after anesthetic withdrawal.
Video-EEG monitoring revealed diffuse asymmetric slowing with
right preponderance and frequent rhythmic delta activity in the anterior
regions of the right hemisphere (Fig. 1). Sleep patterns were absent. No
correlation could be found between abnormal movements and EEG
tracing, with most abnormal movements occurring without evidence
of ictal patterns (Fig. 2, Video 4). Unequivocal ictal activity was infre-
quent and was either clinically silent or associated with movements
similar to the movements observed in the absence of ictal patterns.
Diagnostic work-upwas complemented with systemic autoimmune
study (ANAs, anti-dsDNA, anti-SSA, anti-SSB, anti-Sm, anti-RNP, anti-
Scl70, anti-Jo-1, p-ANCA, c-ANCA, anti-TPO and anti-tiroglobulin) and
search for occult malignancy (tumor markers: CEA, CA19-9, CYFRA
21.1, NSE, β-HCG, PSA, alpha-fetoprotein; anti-neuronal antibodies:
anti-Hu, Ri, Yo, amphiphysin, MA2, CV2; thorax X-ray; abdominal
and testicular ultrasound), without relevant ﬁndings. CSF analysis
was repeated revealing normal cytochemistry, negative 14.3.3 protein
and positive oligoclonal bands unmatched in serum. Autoimmune
encephalitis antibody screening was requested, including antibodiesFig. 1. Electroencephalogram (bipolar montage) showing asymmetric diffuse slow activity wit
(1.5 Hz) is observed in the right frontal and temporal regions.against NMDAR, voltage-gated potassium channel (VGKC) complexes,
gamma-aminobutyric acid type B (GABAB) receptor and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. Consid-
ering the clinical suspicion of autoimmune encephalitis, high-dose in-
travenous (IV) methylprednisolone (MP) was administered for 5 days,
followed by MP 1 mg/kg/day. No improvement occurred after 5 days
of MP, so IV immunoglobulin (IVIG) was started (25 g/day, for
5 days). As the patient's clinical status continued progressively worsen-
ing after IVIG, plasma exchange (PE) on alternate days was tried. An
improvement in alertness with short periods of interaction with the
environment and brief periods of posterior rhythmic activity in EEG
was observed after the third PE session. However, PE had to be
discontinued after the fourth session due to hemoptysis secondary to
hypoﬁbrinogenemia, associated with severe anemia and hypotension.
Nevertheless, 7 days later, after resolution of these medical complica-
tions, gradual improvement started with recovery of spontaneous
ventilation and progressively longer periods of interaction with the
environment.
BrainMRIwas repeated andwhole body positron emission tomogra-
phy (PET) scan was performed, without signiﬁcant ﬁndings. Brain
18F-FDG-PET scan revealed hypometabolism in the left hemisphere
and relative hypermetabolism in the frontal and temporal regions of
the right hemisphere (Fig. 3). Auto-antibody analysis identiﬁed anti-
NMDAR antibodies in serum and CSF.
Signiﬁcant progressive clinical improvement occurred in the
following months, with stabilization of the autonomic functions and
normalization of the sleep–alertness cycle, including the presence of
sleep patterns in the EEG, and subsequent recovery of motor skills and
language. Behavioral changes, namely psychomotor restlessness and
aggressiveness, were initially reported, but gradually resolved during
the ﬁrst four months of convalescence. Immunosuppressive therapy
with azathioprine (50 mg/day) was started after immunotherapy
withdrawal.
After one year, neuropsychological assessment reveals moderate
frontal lobe dysfunction characterized by apathy, impulsivity and
dysexecutive syndrome, and EEG shows persistence of slow activity inh preponderance to the anterior regions of the right hemisphere. Rhythmic delta activity
Fig. 2. Electroencephalogram (bipolarmontage) during oromandibular and left upper limb dyskineticmovements (Video 4) revealingmovement artifacts and no identiﬁable ictal pattern.
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scan was repeated without any relevant ﬁndings. Brain 18F-FDG-PET
scan shows signiﬁcant improvement of brain metabolism (Fig. 5).Fig. 3. Brain 18F-FDG PET showing diffuse hypometabolism and relative right fronto-
temporal hypermetabolism.2. Discussion
Anti-NMDAR encephalitis has been described recently and its clini-
cal features are still being deﬁned. Several cases have been reported
since the ﬁrst description and it is now believed to be more common
than initially thought and to be the most frequent type of antibody-
associated encephalitis [2,3].
Our patient symptom progression, with psychiatric manifestations
followed by seizures and diminished consciousness with abnormal
movements, dysautonomia and central hypoventilation is in accordance
with the described progression of anti-NMDAR encephalitis [4–6].
However, although insomnia is commonly described as an early pre-
senting sign of the disease, the authors have not found another report
of total insomnia as the ﬁrst presentation of anti-NMDAR encephalitis.
In the reported case, the presence of total insomnia resistant to benzo-
diazepines followed by behavioral symptoms, vigilance disturbance,
autonomic hyperactivation and abnormal movements could resemble
sporadic FI.
FI usually presentswith a progressive decrease of sleepwhich culmi-
nates in total insomnia resistant to medication as benzodiazepines
and barbiturates and accompanied by progressive disturbance of vigi-
lance, attention andmemory, personality changes, motor abnormalities
consisting of peculiar oneiric behaviors (motor gestures which are
believed to be related to a dream content) and, in some patients,
autonomic hyperactivation, including arterial hypertension, slight eve-
ning pyrexia, diaphoresis, increased lacrimation and sialorrhea [7,8].
However, FI characteristically has a slower progression, with about
ﬁve months of progressive sleep decrease and behavioral and psychiat-
ric changes before the patient presentswith total insomnia [1,9–12] and
usually other motor abnormalities develop with disease progression in-
cluding myoclonus, ataxia, pyramidal signs, dysarthria and dysphagia
[7]. Seizures may occur in both conditions [4,5,13].
In anti-NMDAR encephalitis, EEG usually reveals non-speciﬁc slow
and disorganized activity and sporadic ictal patterns that evolve to a
slow continuous rhythmic theta–delta activity [4–6,14]. Characteristi-
cally, no correlation is found between EEG activity and abnormalmove-
ments and these movements do not respond to antiepileptic treatment
Fig. 4. EEG (bipolar montage) after one year, revealing persistence of slow activity in the right hemisphere anterior regions.
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in differentiating epileptic seizures and nonepileptic abnormal move-
ments, avoiding overtreatment with antiepileptics or anesthetics [16].
Brain MRI may be normal or present subtle and usually transient T2 or
FLAIR signal hyperintensities in variable locations, usually without signif-
icant correlation with the clinical manifestations [4–6,17]. Brain PET scan
abnormalities are non-speciﬁc and are usually variable, multifocal and
involve cortical and subcortical regions [4,18–21]. Recently, a report
analyzing brain PET scan of six patients with anti-NMDAR encephalitis
detected a gradient of cerebralmetabolism from frontotemporal to occip-
ital areas [22]. The diagnosis is based on the identiﬁcation of anti-NMDAR
antibodies in serum or CSF [4,6,23].
In FI, EEG identiﬁes progressive loss of sleep spindles and slowwave
sleep, abnormal REM sleep stages and disruption of sleep cyclic organi-
zation [8,24]. The reported case alerts that similarly to FI, sleep patterns
may be abnormal or even absent in anti-NMDAR encephalitis. BrainMRIFig. 5. Brain 18F-FDG PET after one year showing signiﬁcant improvement of brain
metabolism.in patients with FI usually only presents non-speciﬁc cortical cerebral
and cerebellar atrophy in late stages and brain PET scan typically
shows thalamic and cingulated cortex hypometabolism [7]. In sporadic
FI, 14.3.3 protein may be detected in CSF with an estimated positive
predictive value of 95% [7].
Pathophysiologically, anti-NMDAR antibodies induce selective and
reversible internalization of the post-synaptic NMDAR with de-
crease of glutamatergic function, essential to synaptic transmission
and cerebral plasticity [4,5,25]. Current theories postulate that in-
activation of GABAergic neurons leads to disinhibition of excitatory
pathways resulting in frontostriatal syndrome and activation of
brainstem central pattern generators inducing abnormal move-
ments [4]. Hypoventilation is proposed to result from the direct ef-
fect of antibodies on the medullary-pontine respiratory network
and dysautonomia from the effect of the antibodies on the dopami-
nergic, noradrenergic and cholinergic systems which have NMDAR
[4].
FI is believed to result from a disturbance in the thalamolimbic
system involved in the regulation of the wake–sleep cycle and other
hormonal and circadian functions, resulting in a shift to persistent
wake behavior and autonomic hyperactivation [7,8,24,26].
While FI currently has no treatment, presenting a fatal disclosure
after 13 to 73 months [1,10–12], anti-NMDAR encephalitis is treatable,
with about 75 to 81% of patients presenting signiﬁcant improvement
after treatment [4,5,27]. First-line treatment consists of immunotherapy
(corticosteroids, IVIG and/or PE) and, when an associated neoplasm is
found, tumor removal [4,6,27].
NMDAR internalization by the antibodies is potentially reversible
after antibody removalwith immunotherapies [5,14], thus the neuronal
dysfunction induced by the antibodies is potentially reversible even in
cases of severe and prolonged disease. Therefore, treatment must
always be performed irrespective of disease duration.
When no improvement occurs with ﬁrst-line treatment and there
is a conﬁrmed diagnosis or a strong clinical suspicion of anti-NMDAR
encephalitis, second-line treatment with rituximab and/or cyclophos-
phamide must be tried as it may improve patient outcome [4,6].
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symptom onset [4]. Social behavior and executive function recovery is
usually prolonged andmay be incomplete, with a signiﬁcant proportion
of patients with considerable recovery remaining with frontal dysfunc-
tion [4–6,28]. Relapses occur in 12 to 25% of patients [5,15,29,30], more
commonly in patients without associated tumor, so immunosuppres-
sion with azathioprine or mycophenolate mofetil during at least
1 year after withdrawal of the initial immunotherapies and periodic
tumor screening is advised in these patients [4–6].
In conclusion, this report alerts that anti-NMDAR encephalitis may
ﬁrst present with severe or even total insomnia, followed by behavioral
and cognitive changes, alertness disturbance, abnormalmovements and
dysautonomia. As this presentation may resemble FI, anti-NMDAR
encephalitis should be considered in the differential diagnosis of FI,
especially in sporadic cases. The distinction between the two conditions
is important, as, contrarily to the fatal disclosure of FI, anti-NMDAR
encephalitis is potentially reversible with immunotherapies even in
cases of severe and prolonged disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2013.10.034.Conﬂicts of interest
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